Download PDF

Introduction

This report analyzes the emerging sector of molecular diagnostics. It provides a clear classification, assessing the leading technologies and key tests which are positioned in this exciting area of diagnostics. The current MDx market size and leading players are analyzed, with a market forecast of the MDx segment as well as the total in vitro diagnostic (IVD) market from 2007-13 also provided

Scope

• A definitive classification system for in vitro diagnostics (IVD) and molecular diagnostics (MDx), and the differing regulatory pathways in the US/EU
• Market size and forecast growth rates to 2013 for IVD and MDx segments
• A detailed analysis of emerging 'companion diagnostics' (the synergy of targeted prescription therapies with diagnostics)
• A database detailing c.120 MDx products on the market

Highlights

The MDx market is a small but fast growing segment of the global IVD market, with an estimated 2007-13 CAGR of 14.0%. Total MDx sales are expected to outpace the total IVD market (2007-13 CAGR of 5.0%) over the next six years

Of particular interest is the role of MDx in companion diagnostics (the synergy between targeted prescription pharmaceuticals and molecular diagnostic tests). Datamonitor has identified seven key therapeutics and more than 12 MDx tests which exemplify this marriage

The report also details a MDx database containing more than 120 MDx tests. The key tests are positioned in the therapy areas of infectious diseases, hematology and oncology by key MDx players such as Roche Diagnostics, Gen-Probe, Abbott Molecular and Myriad

Reasons to Purchase

• Compare the differing growth dynamics of the MDx segment and that of the wider IVD market
• Assess the potential of 'companion diagnostics' and its role in influencing physician selection of molecular targeted therapies
• Identify the key diagnostic tests and players in the MDx segment

View Table Of Contents >